Orchestrating gut health™


The future of health is in your gut. EnteroBiotix is pioneering this future

Welcome to the future
of gut health

We’re a specialist pharmaceutical company focused on gut therapeutics

OUR VISION

To be the leader in developing orally administered therapies that harness the full potential of gut ecology to transform patients lives

EnteroBiotix® at a glance

Company summary

Privately-held, clinical-stage biotechnology company focussed on full-spectrum microbiome therapeutics

Head-quartered in Scotland with 50 employees

Raised £47m in equity investment to build platform and deliver clinical data in two high-value indications

Clinical pipeline

Focus: high-value indications linked to microbiome-related impaired gut function

Completed Ph1b in liver cirrhosis with promising data

Ongoing Ph2 trial in IBS-C/D

Ongoing partnered Ph2a clinical trial with Imperial College in Allo-HSCT patients

Core technology & strengths

Innovative stabilising technology for anaerobic microorganisms, delivering ambient temperature stability and diversity

Control over the supply chain, ability to meet and exceed demands

Sophisticated analytical toolkit for precise microbial characterisation

Our approach

Full-spectrum
gut therapeutics

Our pioneering Intestinal Microbial Transfer (IMT) therapies are preventing and treating disease, through the restoration and enhancement of gut microbial ecology

Rebuilding the foundation
of gut health

Not just treating symptoms
Restoring the gut’s foundation by rapidly addressing the balance and function of the microbiome

Full-spectrum microbial ecosystems
Products utilise microorganisms sourced from exceptionally healthy donors with desirable characteristics

Consistent, stable, high-diversity anaerobic microbiota

Unique powder formulation
An off-white, odourless and stable oral capsule, delivering high-diversity anaerobic microbiota. Inter-donor pooling and starting material controls delivers consistency and safety

Beyond limited strains
In contrast to limited defined consortia, the EnteroBiotix approach embraces the full diversity of the microbiome. This ensures a more adaptable, resilient ecosystem that naturally supports a wide range of gut functions without the limitations of narrowly focused products

Promising safety and
efficacy data

Naturally found in healthy humans
Drugs are based on microbes naturally found within the healthy human gut. Available placebo-controlled data suggests drug is safe and well-tolerated

Efficacy signals
Ph1b data in cirrhosis reports that drugs improve local and systemic outcomes, such as gut barrier function and hospital anxiety and depressions scores. Ph2 IBS-C cohort interim analysis has generated efficacy signals

Next-generation platform enables our differentiated approach

  • Number 2®

    In-house donor programme

  • PRISM™

    Sophisticated analytical toolkit

  • AMPLA™

    Proprietary drying technology

  • Manufacturing

    State-of-the-art GMP capabilities

  • Stable drug substance

    Superior characteristics

  • Oral capsules

    Delivered without bowel prep

EBX Newsroom

Meet our pioneering team

EBX is led by an entrepreneurial and experienced management team, supported by a distinguished Board

More about us

Join us in our mission
to orchestrate gut health

If you are passionate about improving the health of others and transforming lives, we are always looking for talented, ambitious, collaborative, and adaptable people

More about careers at EBX

Partnering opportunity

We welcome partnering enquiries about our platform or our pipeline. Get in touch to find out more